New Search

If you are not happy with the results below please do another search

1122 search results for:

121

The PolG Foundation awards over $3.5m in academic grants to pioneer POLG research

The PolG Foundation is a nascent foundation established in 2022, with the mission to support and accelerate research to find effective treatments and a cure for PolG mitochondrial disorders. Among many activities, one central pillar of the foundation is to raise funding and provide grants to world-class investigators of basic science, clinical trial research and […]

122

Hermes Pharma to invest € 25 million to bolster manufacturing capabilities for oral dosage forms

Germany-based Hermes Pharma, a leading expert in user-friendly oral dosage forms, has announced it will invest €25 million to further bolster its manufacturing capabilities. The investment will arm the company with new equipment, increased production and storage capacity, and greater operational efficiency to meet the rapidly growing market demand for user-friendly oral dosage forms. As […]

124

Thermo Fisher plans to expand into proteomics with Olink acquisition

Following agreement by the respective boards of directors, Thermo Fisher Scientific in mid-October announced plans to acquire Olink Holding for US$3.1 billion. The acquisition will enable Thermo Fisher to expand into proteomics and complement its platforms in life sciences and mass spectrometry. Olink offers solutions for advanced proteomics discovery and development.

125

New cleanrooms prompt search for better monitoring system

During preparations for the construction of two new cleanroom facilities, NorthX Biologics, a leading Swedish biological drug manufacturer and process developer, reviewed its environmental monitoring and control procedures, and decided to switch to a new Vaisala system, including almost 150 monitoring locations within cleanrooms and associated facilities.

126

HeartBeat.bio raises €4.5 million to drive development of organoid screening platform for cardiac drug discovery

HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, has closed a €4.5 million pre-series A round co-led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures. The financing enables the completion of a ready-to-use, fully integrated, automated, high-throughput Cardioid Drug Discovery […]

128

The growing spectrum of neural autoantibodies and associated syndromes

By Dr Jacqueline Gosink Autoimmune neurology is a rapidly growing field driven by the ongoing discovery of novel neural autoantibodies associated with recognizable clinical syndromes. These diseases can affect the central, peripheral and autonomic nervous systems and may co-occur with cancer. Today’s testing landscape encompasses more than 60 neural autoantibodies targeting different intracellular proteins, receptors […]

129

Tumour markers in lung cancer: modelling strategies for interpretation of tumour marker changes and potential clinical applications

By Dr F. van Delft, Dr M. Schuurbiers, Dr van den Heuvel and Dr H. van Rossum The development of immunotherapy and other targeted therapies has given rise to significant improvements in the treatment of non-small cell lung cancer. However, some patients do not benefit from these therapies and it is, therefore, important for a […]

130

The Man Van: catching prostate cancer early

We all know that detecting cancer early is the key to obtaining the best treatment outcomes. However, how do you do this when some sectors of the population struggle to access healthcare and does point-of care testing make it possible to take health screening to the people who need it? CLI caught up with Professor […]